InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses
January 24, 2023 06:00 ET
|
InvestmentPitch Media and Hemostemix Inc
VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to...
CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device
May 17, 2018 07:00 ET
|
CellAegis Devices Inc.
TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective...
CellAegis Announces First Distribution Agreement for autoRIC® in Europe
April 24, 2018 07:00 ET
|
CellAegis Devices Inc.
TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for...
CellAegis Strengthens Management Team to Support Future Growth
April 17, 2018 07:00 ET
|
CellAegis Devices Inc.
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and...
CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
April 10, 2018 07:00 ET
|
CellAegis Devices Inc.
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and...